Unsere Universität Wissenschaftliche Publikationen 2018 Gitt AK, Rieber J, Hambrecht R, Brachmann J, Graf K, Horack M, Karmann B, Vyas A, Lautsch D, Ambegaonkar B, Brudi P. Do acute coronary events affect lipid management and cholesterol Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Gitt AK, Lautsch D, Horack M, Baxter CA, Ferrie- res J, De Ferrari G, DYSIS Study Group. Risk for Almahmeed W, Chiang FT, Poh KK, Brudi P, Am- major adverse cardiovascular events estimated begaonkar B. Contemporary data on treatment by the TIMI Risk Score for Secondary Prevention goal attainment in Germany? Results from the practices for low-density lipoprotein cholesterol TRS2P in patients with coronary artery disease Dyslipidemia International Study II. Wien Klin in 6,794 patients with stable coronary heart did not impact lipid lowering treatment in clinical Wochenschr. 2018 Sep 3. DOI: 10.1007/s00508- disease across the world. Data in Brief 2018. practice. Eur Heart J Suppl. 2018.39:566.P5383. 018-1375-3. [Epub ahead of print] 18:1937-1940. ESC 2018. Poh KK, Chee Tang Chin, Khim Leng Tong, Ko Beng JT, Seong J, Yu A, Horack M, Vyas A, Lautsch D, Ambegaonkar B, Brudi P, Gitt AK. Cholesterol goal achievement and lipid-lowering therapy Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrie- res J, Gitt AK. How does the TRS 2P score relate Gitt AK, Lautsch D, Horack M, Ferriéres J, für die Studiengruppe: DYSIS Investigators. Gender Differences in Lipid-Lowering Treatment and to real-world patients? Eur Heart J Cardiovasc LDL-Cholesterol-Target Attainment in Patients in patients with stable or acute coronary heart Pharmacother. 2018;4(2):72-74. disease in Singapore – Results from the Dyslipi- with ACS – Results of DYSIS II ACS. Clin Res Cardi- ol 107 Suppl 1, April 2018 - P1768; DOI: 10.1007/ demia International Study II. Singapore Medical Graham I, Shear C, De Graef P, Boulton C, s00392-018-1216-4. Journal 2018. Accepted manuscript. Catapano AL, Gattis Stough W, Carlsson S C, De Ferrieres J, Lautsch D, Ambegaonkar BM, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Velkovs- Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray K, Robinson JG, Sasiela WJ, Slot KB, Stroes E, Gitt AK, Lautsch D, Horack M, Ferriéres J, für die Studiengruppe: DYSIS Investigators. Better LDL-Cholesterol-Target Attainment in Patients ki-Rouyer M, Horack M, Almahmeed W, Chiang Thuren T, Van der Schueren B, Velkovski-Rouyer with ACS and Type 2 Diabetes – Results of DYSIS F-T, Poh KK, Elisaf M, Brudi P, Gitt AK. Use of M, Wasserman SM, Wiklund O, Zouridakis E. New II ACS. Clin Res Cardiol 107 Suppl 1, April 2018 - guideline-recommended management in esta- strategies for the development of lipid lowering P1802; DOI: 10.1007/s00392-018-1216-4. blished coronary heart disease in the observa- therapies to reduce cardiovascular risk. Eur tional DYSIS II study. International Journal of Heart J Cardiovasc Pharmacother. Cardiology. 2018, 270:21-27. 2018:4(2):119-27. Ferrieres J, Lautsch D, Velkovski-Rouyer M, Ambegaonkar BA, De Ferrari GM, Vyas A, Baxter C, Horack M, Bash L, Al Mahmeed W, Chiang FT, Poh De Ferrari GM, Perna GP, Nicosia A, Guasti L, Casue G, Cuccia C, Picco F, Strazzella C, Totaro R, Cercone S, Canullo L, Lautsch D, Gitt AK, Di Biase M. Available oral lipid lowering agents Liberopoulos E, Rallidis L, Spanoudi F, Xixi E, Gitt A, Horack M, Ashton V, Brudi P, Lautsch D, Am- begaonkar B, Elisaf M. Attainment of Cholesterol KK, Brudi P, Gitt A. Use of guideline-recommen- ded treatments in 10,661 patients with coronary heart disease: Observational multinational DYSIS Target Values in Greece: Results from the Dyslipi- II study. JESFC 2018. Archives of Cardiovascular could bring most high-risk patients to target – an demia International Study II. Archives of Medical Diseases Supplements 2018.9(1):130. estimate based on DYSIS II-Italy. J Cardiovasc Science. 2018. DOI: https://DOI.org/10.5114/ Med (Hagerstown). 2018;19(9):485-490. aoms.2018.73961. Yan BP, Chiang FT, Ambegaonkar B, Brudi P, Horack M, Lautsch D, Vyas A, Gitt AK. Low-densi- ty lipoprotein cholesterol target achievement in Gitt AK, Lautsch D, Horack M, Baxter CA, Ferrieres J, De Ferrari G, DYSIS Study Group. Better LDL-cho- lesterol-target attainment in patients with ACS Hypertens 2018; 36: 110-118. patients surviving an acute coronary syndrome and type 2 diabetes – results of DYSIS II ACS. Eur in Hong Kong and Taiwan – findings from the Heart J Suppl. 2018.39:564.P781. ESC 2018. Dyslipidemia International Study II. International Journal of Cardiology. 2018;265:1-5. Piringer G, Fridrik M, Fridrik A, Leiherer A, Zaber- nigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal A, Burgstaller S, Gnant M, Thaler J; Aus- Leiherer A, Mündlein A, Säly CH, Rein P, Von- bank A, Kinz E, Brandtner EM, Fraunberger P, Drexel H. The value of Uromodulin as a new se- rum marker to predict decline in renal function. J